Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LB1908 · 1 trial · 4 indications
Multiple doses will be tested to establish a recommended dose.
Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study.
| Arm | Type | Description |
|---|---|---|
| Experimental LB1908 | EXPERIMENTAL | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells |
| Name | Type | Description |
|---|---|---|
| LB1908 | BIOLOGICAL | Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells |
Inclusion Criteria: For inclusion in the study, all of the following inclusion criteria must be fulfilled. 1. Be willing and able to provide written informed consent. 2. Be a female or male ≥ 18 and ≤ 75 years old at the time of signing of the prescreening ICF. 3. For Part A and Part B Cohort MR1 ...
Top 20 of 47 competitors
LB1908 is an investigational monoclonal antibody being developed by Legend Biotech Corporation for gastric cancer. It is designed to bind CLDN18.2, a protein target, and is currently in Phase 1 clinical development. It has not been approved by the FDA and remains an investigational therapy in early-stage testing.
LB1908 is being studied for gastric cancer, including gastroesophageal junction cancer, esophageal cancer, and pancreatic cancer. The Phase 1 trial enrolls adults with unresectable, locally advanced, or metastatic disease. Because it is still in Phase 1 testing, LB1908 is investigational and is not yet an approved treatment for gastric cancer or any other indication.
LB1908 targets CLDN18.2, a protein also known as claudin 18.2. This target is a tight junction protein expressed on the surface of certain tumor cells, and the antibody is designed to bind it. The Phase 1 study selects patients based on this biomarker, meaning participants must show CLDN18.2 expression to enroll.
Legend Biotech Corporation is developing LB1908. The company trades on the Nasdaq under the ticker symbol LEGN. Legend Biotech is the sole sponsor listed for the Phase 1 trial of LB1908 in gastric and related cancers.
LB1908 is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication. The single Phase 1 trial is currently active but not recruiting new participants, with a planned enrollment of 56 patients.
LB1908 is being evaluated in one Phase 1 trial, NCT05539430, titled Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction, Esophageal, or Pancreatic Adenocarcinoma. The study is active but not recruiting, enrolls 56 participants, is uncontrolled, and is conducted in the United States.